Efficacy and Safety of Baricitinib in Patients with Severe COVID-19: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2023 Dec 5

PMID 38050265

Authors

Wenxin Song

Shishen Sun

Yilong Feng

Liujun Liu

Tianqi Gao

Shaoxiang Xian

Jie Chen

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the efficacy and safety of baricitinib in patients with severe coronavirus disease 2019 (COVID-19).

Methods: Databases were searched for studies that compared the clinical efficacy and adverse effects of baricitinib with standard therapy for the treatment of severe COVID-19 and clearly reported relevant outcomes published until December 31, 2022. The corresponding data were extracted from these studies. A fixed-effects model was used to calculate the pooled estimates. The study protocol can be accessed at PROSPERO (CRD42023394173).

Results: The baricitinib group had a significantly lower mortality rate and proportion of patients who received mechanical ventilation than the control group (OR = 0.61, 0.57; P = .008, 0.02; 95% CI 0.42-0.88; 0.35-0.92; I2 = 71% and 86%, respectively). The length of hospital stay and rates of severe adverse events were not significantly different between the 2 groups.

Conclusion: Baricitinib reduces mortality and mechanical ventilation requirements in patients with severe COVID-19. Therefore, we developed a comprehensive understanding of the role of baricitinib in patients with severe COVID-19.

Citing Articles

Effect of methylprednisolone in reducing severe COVID-19 and mortality in high-risk patients: A retrospective study.

Xiao Y, Wang J, Yang K, Jiang M, Luo J, Chen K SAGE Open Med. 2024; 12:20503121241276683.

PMID: 39257516 PMC: 11384515. DOI: 10.1177/20503121241276683.

Harnessing immunity: Immunomodulatory therapies in COVID-19.

Velikova T, Valkov H, Aleksandrova A, Peshevska-Sekulovska M, Sekulovski M, Shumnalieva R World J Virol. 2024; 13(2):92521.

PMID: 38984079 PMC: 11229839. DOI: 10.5501/wjv.v13.i2.92521.

Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.

Boon A, Bricker T, Fritch E, Leist S, Gully K, Baric R J Virol. 2024; 98(5):e0190323.

PMID: 38593045 PMC: 11092322. DOI: 10.1128/jvi.01903-23.

IRF1 Mediates Growth Arrest and the Induction of a Secretory Phenotype in Alveolar Epithelial Cells in Response to Inflammatory Cytokines IFNγ/TNFα.

Recchia Luciani G, Barilli A, Visigalli R, Sala R, DallAsta V, Rotoli B Int J Mol Sci. 2024; 25(6).

PMID: 38542436 PMC: 10970306. DOI: 10.3390/ijms25063463.

References

So J, Umeh C, Noriega S, Stratton E, Aseri M, Gupta R . Use of Baricitinib in Combination With Remdesivir and Steroid in COVID-19 Treatment: A Multicenter Retrospective Study. Cureus. 2022; 13(12):e20620. PMC: 8786563. DOI: 10.7759/cureus.20620. View

Abizanda P, Calbo Mayo J, Mas Romero M, Cortes Zamora E, Tabernero Sahuquillo M, Romero Rizos L . Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J Am Geriatr Soc. 2021; 69(10):2752-2758. PMC: 8447356. DOI: 10.1111/jgs.17357. View

Kim M, An M, Kim W, Hwang T . Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis. PLoS Med. 2020; 17(12):e1003501. PMC: 7794037. DOI: 10.1371/journal.pmed.1003501. View

Wesley Ely E, Ramanan A, Kartman C, de Bono S, Liao R, Piruzeli M . Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled.... Lancet Respir Med. 2022; 10(4):327-336. PMC: 8813065. DOI: 10.1016/S2213-2600(22)00006-6. View

Najjar-Debbiny R, Gronich N, Weber G, Khoury J, Amar M, Stein N . Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis. 2022; 76(3):e342-e349. PMC: 9214014. DOI: 10.1093/cid/ciac443. View

Titanji B, Farley M, Mehta A, Connor-Schuler R, Moanna A, Cribbs S . Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019. Clin Infect Dis. 2020; 72(7):1247-1250. PMC: 7337637. DOI: 10.1093/cid/ciaa879. View

Cherian J, Eerike M, Bagepally B, Das S, Panda S . Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. Front Pharmacol. 2022; 13:1004308. PMC: 9624173. DOI: 10.3389/fphar.2022.1004308. View

Que Y, Hu C, Wan K, Hu P, Wang R, Luo J . Cytokine release syndrome in COVID-19: a major mechanism of morbidity and mortality. Int Rev Immunol. 2021; 41(2):217-230. PMC: 7919105. DOI: 10.1080/08830185.2021.1884248. View

Ghoreschi K, Laurence A, OShea J . Janus kinases in immune cell signaling. Immunol Rev. 2009; 228(1):273-87. PMC: 2782696. DOI: 10.1111/j.1600-065X.2008.00754.x. View

10.

Andrews J, Guyatt G, Oxman A, Alderson P, Dahm P, Falck-Ytter Y . GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013; 66(7):719-25. DOI: 10.1016/j.jclinepi.2012.03.013. View

11.

van de Veerdonk F, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R . A guide to immunotherapy for COVID-19. Nat Med. 2022; 28(1):39-50. DOI: 10.1038/s41591-021-01643-9. View

12.

Zhang X, Zhang Y, Qiao W, Zhang J, Qi Z . Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19. Int Immunopharmacol. 2020; 86:106749. PMC: 7328558. DOI: 10.1016/j.intimp.2020.106749. View

13.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

14.

Fernando K, Menon S, Jansen K, Naik P, Nucci G, Roberts J . Achieving end-to-end success in the clinic: Pfizer's learnings on R&D productivity. Drug Discov Today. 2021; 27(3):697-704. PMC: 8719639. DOI: 10.1016/j.drudis.2021.12.010. View

15.

Hasan M, Rabbani R, Anam A, Huq S, Polash M, Nessa S . Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh. BMC Infect Dis. 2021; 21(1):427. PMC: 8102838. DOI: 10.1186/s12879-021-06119-2. View

16.

Tanimoto T, Tada S, Fujita S, Hirakawa T, Matsumura M, Isoyama S . Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study. Respir Investig. 2022; 60(3):418-424. PMC: 8898743. DOI: 10.1016/j.resinv.2022.02.004. View

17.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

18.

Schiavo J . PROSPERO: An International Register of Systematic Review Protocols. Med Ref Serv Q. 2019; 38(2):171-180. DOI: 10.1080/02763869.2019.1588072. View

19.

Masia M, Padilla S, Garcia J, Garcia-Abellan J, Navarro A, Guillen L . Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. Front Med (Lausanne). 2021; 8:749657. PMC: 8606519. DOI: 10.3389/fmed.2021.749657. View

20.

Allan M, Lievre M, Laurenson-Schafer H, De Barros S, Jinnai Y, Andrews S . The World Health Organization COVID-19 surveillance database. Int J Equity Health. 2022; 21(Suppl 3):167. PMC: 9685131. DOI: 10.1186/s12939-022-01767-5. View